CATALYST PHARMACEUTICALS, INC. Annual Income Tax Expense (Benefit) in USD from 2012 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Catalyst Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2012 to 2023.
  • Catalyst Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $13.3M.
  • Catalyst Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $46M, a 145% increase year-over-year.
  • Catalyst Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $23.1M, a 6.75% increase from 2022.
  • Catalyst Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was $21.6M, a 64.1% increase from 2021.
  • Catalyst Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2021 was $13.2M.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.